Stugeron 15 is effective in the control of motion sickness.
Stugeron 15 should preferably be taken after meals.
Adults, elderly and children over 12 years:
2 tablets 2 hours before you travel and 1 tablet every 8 hours during your journey.
Children 5 to 12 years:
One half the adult dose.
Method of administration: Oral
Stugeron should not be given to patients with known hypersensitivity to cinnarizine or to any of the excipients listed in section 6.1
As with other antihistamines, Stugeron may cause epigastric discomfort; taking it after meals may diminish gastric irritation.
In patients with Parkinson’s disease, Stugeron should only be given if the advantages outweigh the possible risk of aggravating this disease.
Use of cinnarizine should be avoided in porphyria.
There have been no specific studies in hepatic or renal dysfunction. Stugeron should be used with care in patients with hepatic or renal insufficiency.
Patients with rare hereditary problems of fructose or galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, should not take this medicine because it contains lactose and sucrose.
Stugeron may cause somnolence, especially at the start of treatment. Therefore caution should be taken when alcohol, central nervous system (CNS) depressants or tricyclic antidepressants are used concomitantly. Please also refer to section 4.5 Interactions with Other Medicinal Products and Other Forms of Interaction.
Because of its antihistamine effect, Stugeron may prevent an otherwise positive reaction to dermal reactivity indicators if used within 4 days prior to testing.
Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either of these drugs or of Stugeron.
Because of its antihistamine effect, Stugeron may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing. Also refer to section 4.4 Special Warnings and Precautions for Use.
The safety of Stugeron in human pregnancy has not been established although studies in animals have not demonstrated teratogenic effects. As with other drugs it is not advisable to administer Stugeron in pregnancy.
There are no data on the excretion of Stugeron in human breast milk. Use of Stugeron is not recommended in nursing mothers.
Stugeron may cause drowsiness, especially at the start of treatment; patients affected in this way should not drive or operate machinery.